Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Edwards Lifesciences ( (EW) ) just unveiled an update.
Edwards Lifesciences announced on May 4, 2026, that Theodora (“Doretta”) Mistras will become corporate vice president and chief financial officer effective May 29, 2026, succeeding longtime CFO Scott Ullem. Her appointment follows Ullem’s planned transition and extends Edwards’ emphasis on continuity in financial leadership.
Mistras joins from Viatris, where she has served as CFO since March 2024 after a long career in healthcare investment banking at Citigroup and Goldman Sachs, and she receives a compensation package weighted toward equity to align her with shareholders. Edwards’ chief executive, Bernard Zovighian, highlighted her capital markets and strategy experience as key to executing the company’s growth agenda and sustaining strong financial results for patients, customers and investors.
Her offer includes a $925,000 base salary, a target annual bonus equal to at least her salary, a $2.013 million sign-on bonus subject to repayment conditions, and $8 million in restricted stock units with time-based vesting and protective provisions in certain termination scenarios. She will also be eligible for ongoing annual equity awards, severance protections comparable to other senior executives, and relocation support, underscoring the strategic importance Edwards places on the CFO role during this leadership transition.
The most recent analyst rating on (EW) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
The score is driven primarily by strong financial quality (high margins and an exceptionally low-debt balance sheet) and a constructive earnings outlook with confident 2026 guidance and continued structural-heart momentum. These strengths are tempered by an expensive valuation (high P/E, no dividend support) and mixed near-term technical momentum (negative MACD despite trading above key moving averages).
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
Edwards Lifesciences is a leading global structural heart innovation company focused on developing breakthrough cardiovascular technologies to improve patient lives. Through clinical evidence and partnerships with clinicians and healthcare stakeholders, the Irvine, Calif.-based group targets life-changing therapies for patients with advanced heart disease worldwide.
The company’s portfolio and strategy position it at the high end of the medical technology market, where it aims to pair innovation with durable financial performance. Its patient-focused culture and close collaboration with hospitals underpin its efforts to defend and expand its leadership in transcatheter heart valves and related therapies.
Average Trading Volume: 5,279,751
Technical Sentiment Signal: Strong Buy
Current Market Cap: $48.42B
For detailed information about EW stock, go to TipRanks’ Stock Analysis page.